HOECHST PAKISTAN LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,400 PKR | -2.04% |
|
-3.45% | +16.67% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 18.56B 66.72M | Sales 2023 | 21.37B 76.82M | Capitalization | 11.57B 41.61M |
|---|---|---|---|---|---|
| Net income 2022 | 167M 600K | Net income 2023 | 361M 1.3M | EV / Sales 2022 | 0.57 x |
| Net Debt 2022 | 1.4B 5.03M | Net cash position 2023 | 1.01B 3.62M | EV / Sales 2023 | 0.49 x |
| P/E ratio 2022 |
55.4
x | P/E ratio 2023 |
32.1
x | Employees | 734 |
| Yield 2022 * |
-
| Yield 2023 |
2.5% | Free-Float | 7.83% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -6.40% | ||
| 1 week | -1.44% | ||
| Current month | +16.19% | ||
| 1 month | +2.27% | ||
| 3 months | +8.18% | ||
| 6 months | +47.72% | ||
| Current year | +19.10% |
1 week
1 330.00
1 541.00
1 month
1 230.001 541.00
Current year
1 210.011 541.00
1 year
650.001 541.00
3 years
492.001 541.00
5 years
436.201 541.00
10 years
436.203 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sajjad Iftikhar
CEO | Chief Executive Officer | - | 23-04-27 |
| Director of Finance/CFO | - | - | |
Saiyed Raza
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Syed Hyder Ali
BRD | Director/Board Member | - | 87-02-21 |
Syed Babar Ali
CHM | Chairman | - | 76-12-31 |
Arshad Gohar
BRD | Director/Board Member | - | 11-02-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 1,400 | -2.04% | 12 625 |
| 24-05-20 | 1,429 | -6.40% | 56 |
| 24-05-17 | 1,527 | +6.48% | 17,422 |
| 24-05-16 | 1,434 | -1.40% | 16,801 |
| 24-05-15 | 1,454 | -1.73% | 9,606 |
End-of-day quote Pakistan S.E., May 19, 2024
More quotes
Hoechst Pakistan Limited is a pharmaceutical company. The Company is engaged in the manufacturing, selling and trading of pharmaceutical and related products. The Company offers solutions for various therapeutic areas, such as antibiotics, cardiology, diabetes, pain and allergy and others. Its patient programs address unmet needs around access and education across Pakistan to support people with diabetes. It provides and delivers therapeutic solutions for cardiovascular diseases (CVDs) and works with healthcare professionals to impart awareness and knowledge to patients who are at risk of developing heart diseases. Its products include ampoules, vials, tablets and capsules, and oral liquids. Its brands include Flagyl, Clexane, No-Spa, Lantus, Amaryl, Claforan, Haemaccel, Enterogermina, Plavix and Selsun Blue. Selsun Blue helps treat and prevent dandruff symptoms by targeting dandruff from the source and thus soothes irritated scalp, fights itch and controls visible flakes.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +19.10% | 49.53M | |
| +34.35% | 705B | |
| +29.39% | 583B | |
| -3.49% | 364B | |
| +20.15% | 332B | |
| +6.19% | 291B | |
| +14.11% | 238B | |
| -3.03% | 210B | |
| +10.02% | 209B | |
| +9.21% | 169B |
- Stock Market
- Equities
- HPL Stock
